Generic Cyclobenzaprine Hcl

Buy Generic Cyclobenzaprine Hcl () without prescription in Canada

In our Canadian pharmacy, you can buy Cyclobenzaprine HCl without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Cyclobenzaprine hydrochloride is a centrally‑acting skeletal muscle relaxant used as an adjunct to rest and physical therapy for the short‑term relief of painful muscle spasms associated with acute musculoskeletal conditions, such as back or neck strains. Although its exact mechanism is not fully established, it acts primarily within the brainstem to reduce tonic somatic motor activity, influencing both gamma and alpha motor neurons. Its pharmacological profile is similar to that of tricyclic antidepressants, which accounts for both its muscle‑relaxant effects and its characteristic side‑effect profile, including significant sedation.

Usual adult dose: The usual dose of the extended‑release capsule is 15 mg taken once daily, at approximately the same time each day. Some patients may require an increase to 30 mg once daily depending on their clinical response. The capsule should be swallowed whole or may be opened and the contents sprinkled onto a tablespoon of applesauce, which should be consumed immediately without chewing. This medication is intended for short‑term use only, typically for 2 to 3 weeks, and should not be taken for longer than prescribed.

Dosage form: Extended‑release oral capsule containing 15 mg of cyclobenzaprine hydrochloride.

Onset of action: Clinical effects, including muscle relaxation and sedation, typically become apparent within 30 to 60 minutes of taking an immediate‑release dose. With the extended‑release formulation, plasma concentrations rise more gradually, providing sustained relief over 24 hours.

Duration of action: The extended‑release 15 mg capsule provides a therapeutic effect for approximately 24 hours, allowing for once‑daily dosing. The elimination half‑life of cyclobenzaprine ranges from 8 to 37 hours, with a long terminal half‑life that supports this extended duration.

Alcohol recommendation: Alcohol consumption should be strictly avoided during treatment with Cyclobenzaprine HCl. Alcohol can severely worsen the drowsiness, dizziness, and impaired coordination caused by this medication, increasing the risk of falls, accidents, and respiratory depression. Patients should not consume alcohol until they know how this drug affects them.

Most common side effects: The most common side effects are related to its anticholinergic and CNS‑depressant properties and include drowsiness (occurring in up to 40% of patients), dry mouth, dizziness, and fatigue. Other common effects include headache, nausea, constipation, and blurred vision. These effects are dose‑dependent and may lessen over time, but they can be significant enough to limit daily activities.

Would you like to try Cyclobenzaprine HCl without a prescription?

General Information about Cyclobenzaprine HCl

• INN (International Nonproprietary Name): Cyclobenzaprine Hydrochloride
• Brand names available in Canada: Flexeril® is the original brand name, though it has been discontinued and is no longer actively marketed. Widely available generic versions include: AG‑Cyclobenzaprine, APO‑Cyclobenzaprine, AURO‑Cyclobenzaprine, DOM‑Cyclobenzaprine, JAMP‑Cyclobenzaprine, PMS‑Cyclobenzaprine, RIVA‑Cyclobenzaprine, TEVA‑Cyclobenzaprine, and Sandoz Cyclobenzaprine, among others. The immediate‑release 10 mg tablet is the most commonly prescribed formulation in Canada.
• ATC code: M03BX08 (other centrally acting agents)
• Dosage forms and strengths: Immediate‑release tablets: 5 mg and 10 mg. Extended‑release capsules: 15 mg and 30 mg. The 15 mg extended‑release capsule is a once‑daily formulation.
• Manufacturers in Canada: Janssen Inc. (original manufacturer of Flexeril), Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., Auro Pharma Inc., JAMP Pharma Corporation, Sanis Health Inc., Sivem Pharmaceuticals ULC, Angita Pharma Inc., Orimed Pharma Inc., and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Multiple generic formulations are currently marketed and available by prescription. The original brand Flexeril is now cancelled post‑market.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act.

Mechanism of Action and Pharmacology

Cyclobenzaprine hydrochloride is a centrally acting skeletal muscle relaxant that is structurally and pharmacologically related to tricyclic antidepressants. The precise mechanism of action of cyclobenzaprine has not been fully determined, but it is known to act primarily within the central nervous system, at the level of the brainstem, to reduce tonic somatic motor activity. It influences both gamma and alpha motor neurons, leading to a reduction in local skeletal muscle spasm without directly interfering with neuromuscular junction function or muscle contractility. Cyclobenzaprine does not work peripherally on the muscle itself, which distinguishes it from antispastic agents like baclofen. It has also been shown to be a potent non‑competitive antagonist of histamine H1 receptors, which accounts for its prominent sedative effects. In addition, it potentiates norepinephrine and binds to serotonin receptors in the brain, further modulating descending motor pathways. Cyclobenzaprine is ineffective in muscle spasm due to central nervous system disease, such as cerebral palsy or spinal cord injury. After oral administration, cyclobenzaprine is well absorbed but undergoes significant first‑pass metabolism. The extended‑release formulation delivers the drug slowly, with peak plasma concentrations occurring approximately 7 hours after a single 15 mg dose. The drug is extensively metabolized in the liver, primarily by cytochrome P450 3A4, 1A2, and to a lesser extent by 2D6, and is excreted mainly as glucuronide conjugates in the urine. The elimination half‑life is approximately 8 to 37 hours, which can be prolonged in the elderly and in patients with hepatic impairment. The extended‑release capsule should not be used in geriatric patients or in those with moderate to severe hepatic impairment.

Indications

• Acute Musculoskeletal Conditions: As an adjunct to rest and physical therapy for the short‑term (2–3 weeks) relief of painful muscle spasms associated with acute, painful musculoskeletal conditions, such as back pain, neck pain, and muscle strains.
• Fibromyalgia (Off‑label): Cyclobenzaprine is sometimes prescribed off‑label for the treatment of fibromyalgia, particularly to improve sleep quality and reduce pain. A sublingual formulation (Tonmya) has been studied and approved in the United States for this indication, though the standard oral tablet is used off‑label in Canada.
• Cyclobenzaprine is not effective for the treatment of muscle spasm due to cerebral palsy, spinal cord disease, or other central nervous system disorders.
• It is not recommended for use in children under 15 years of age.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: There are no adequate and well‑controlled studies in pregnant women. Cyclobenzaprine should be used during pregnancy only if the potential benefit clearly outweighs the potential risk. A pregnancy test may be considered before starting treatment in women of childbearing potential, and effective contraception should be used during therapy and for 2 weeks after the last dose.
• Breastfeeding: Cyclobenzaprine passes into breast milk and may harm a nursing infant. Breastfeeding is not recommended during treatment. A decision should be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of the medication to the mother.
• Paediatrics (< 15 years): The safety and effectiveness of cyclobenzaprine in children under 15 years of age have not been established. Use is not recommended in this population.
• Elderly (≥ 65 years): The extended‑release capsule should not be used in patients aged 65 years or older due to an increased risk of adverse effects, including confusion, sedation, falls, and cardiac arrhythmias. If an immediate‑release formulation is used, a lower starting dose (e.g., 5 mg) and less frequent dosing are recommended, with slow upward titration only if tolerated.
• Hepatic impairment: Cyclobenzaprine is extensively metabolized in the liver. In patients with mild hepatic impairment, initiate immediate‑release cyclobenzaprine at 5 mg and increase slowly. Extended‑release capsules are not recommended in patients with hepatic impairment of any severity. Use in moderate or severe hepatic impairment is contraindicated.
• Renal impairment: Cyclobenzaprine should be used with caution in patients with renal impairment. No specific dosage adjustment is provided, but the drug and its metabolites are excreted renally, and accumulation may occur.
• Cardiovascular disease: Cyclobenzaprine is contraindicated in patients with arrhythmias, heart block, conduction disorders, congestive heart failure, and during the acute recovery phase of a myocardial infarction. It possesses type IA antiarrhythmic properties similar to quinidine and can cause QRS widening and QT prolongation, particularly in overdose. Use with caution in patients with a history of ischaemic heart disease.
• Hyperthyroidism: Cyclobenzaprine is contraindicated in patients with hyperthyroidism, as the combination may increase the risk of cardiac arrhythmias.
• Angle‑closure glaucoma: Cyclobenzaprine should be used with caution in patients with a history of glaucoma or increased intraocular pressure due to its anticholinergic effects.
• Urinary retention: Use with caution in patients with clinically significant prostatic hyperplasia or a history of urinary retention.
• Seizure disorders: Cyclobenzaprine may lower the seizure threshold; use with caution in patients with epilepsy or a history of seizures.
• Serotonin syndrome: Cyclobenzaprine, particularly when combined with other serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs, triptans, fentanyl, lithium, tramadol), may cause a potentially life‑threatening serotonin syndrome. Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal upset. Seek immediate medical attention if these symptoms occur.
• Allergy: Do not take Cyclobenzaprine HCl if you have a known hypersensitivity to cyclobenzaprine or any of its excipients.

Driving and alcohol

Cyclobenzaprine HCl causes significant drowsiness, dizziness, and blurred vision, and can severely impair the mental alertness and physical coordination required for driving or operating machinery. Patients should not drive, operate heavy machinery, or engage in potentially hazardous activities until they have determined how the medication affects them. Alcohol must be strictly avoided during treatment with Cyclobenzaprine HCl. The combination of cyclobenzaprine with alcohol or other central nervous system depressants can lead to profound sedation, respiratory depression, and severely impaired psychomotor performance.

Dosage Instructions

• Extended‑release capsule (15 mg): The recommended dose is one 15 mg capsule taken orally once daily, at approximately the same time each day. Some patients may require up to 30 mg once daily based on clinical response and tolerability. The capsule should be swallowed whole or may be opened and the contents sprinkled onto a tablespoon of applesauce and consumed immediately without chewing. The applesauce should be swallowed immediately, and the mouth should be rinsed to ensure all of the capsule contents have been ingested.
• Duration of therapy: Cyclobenzaprine is intended for short‑term use only, typically for 2 to 3 weeks. There is no evidence of additional benefit beyond this period, and the risk of adverse effects increases with longer use. The prescriber should periodically reassess the need for continued therapy.
• Hepatic impairment: The extended‑release capsule is not recommended for use in patients with hepatic impairment. In patients with mild hepatic impairment, a lower dose of the immediate‑release formulation (5 mg) should be used and titrated slowly. Cyclobenzaprine is contraindicated in moderate to severe hepatic impairment.
• Geriatric use: The extended‑release capsule should not be used in patients aged 65 years or older.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next dose, skip the missed dose and return to the regular once‑daily schedule. Do not double the dose.
• Discontinuation: Abrupt discontinuation after prolonged use may cause withdrawal symptoms such as nausea, headache, and malaise. A gradual dose taper over 2 to 3 weeks is recommended for patients who have been on long‑term therapy, though cyclobenzaprine is generally prescribed only for short periods.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Somnolence (drowsiness, up to 40%), dry mouth (up to 27%), and dizziness (up to 11%).
• Common side effects (1–10%): Fatigue, headache, nausea, constipation, dyspepsia, blurred vision, nervousness, and insomnia.
• Less common but serious side effects: Cardiac arrhythmias (including QRS widening, QT prolongation, and tachycardia), particularly in patients with pre‑existing cardiac conditions or in overdose. Serotonin syndrome (a potentially life‑threatening condition characterized by mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms). Syncope, hypotension, and palpitations. Confusional states, especially in the elderly. Hypersensitivity reactions including rash, urticaria, angioedema, and anaphylaxis have been reported rarely.
• Overdose: An overdose of cyclobenzaprine is a medical emergency that can be fatal, often due to cardiac toxicity including QRS widening, QT prolongation, ventricular arrhythmias, and cardiac arrest. Other symptoms of acute overdose include severe drowsiness, coma, respiratory depression, seizures, and hyperthermia. Immediate hospitalisation with continuous cardiac monitoring and supportive care is required. There is no specific antidote.
• Contraindications: Known hypersensitivity to cyclobenzaprine or any excipient in the formulation. Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation of an MAOI. Acute recovery phase of myocardial infarction. Arrhythmias, heart block, conduction disorders, or congestive heart failure. Hyperthyroidism. Moderate to severe hepatic impairment (for all formulations). The extended‑release capsule is additionally contraindicated in patients ≥ 65 years of age and in patients with any degree of hepatic impairment.

Drug Interactions

• Monoamine oxidase inhibitors (MAOIs) — contraindicated: Concomitant use of cyclobenzaprine with MAOIs (e.g., phenelzine, tranylcypromine, linezolid, intravenous methylene blue) or within 14 days of discontinuing an MAOI may cause serotonin syndrome, severe seizures, and hypertensive crisis. This combination is strictly contraindicated.
• Serotonergic drugs — risk of serotonin syndrome: Concomitant use with other serotonergic agents, including SSRIs (e.g., sertraline, escitalopram), SNRIs (e.g., venlafaxine, duloxetine), tricyclic antidepressants, triptans, fentanyl, tramadol, lithium, buspirone, and St. John's wort, increases the risk of serotonin syndrome. Monitor closely if co‑administration is clinically necessary.
• CNS depressants — additive sedation: Alcohol, benzodiazepines, opioids, sedating antihistamines, barbiturates, and other central nervous system depressants may potentiate the sedative and psychomotor‑impairing effects of cyclobenzaprine. Patients should be warned against driving or operating machinery when such combinations are used.
• Anticholinergic agents — additive anticholinergic effects: Concomitant use with other drugs possessing anticholinergic properties (e.g., antihistamines, antipsychotics, antispasmodics, oxybutynin) may increase the risk of dry mouth, constipation, blurred vision, urinary retention, and confusion, particularly in the elderly.
• CYP3A4 and CYP1A2 inhibitors: Ketoconazole, clarithromycin, erythromycin, ritonavir, fluvoxamine, ciprofloxacin, and other inhibitors of CYP3A4 or CYP1A2 may increase cyclobenzaprine plasma levels, increasing the risk of adverse effects. Dose reduction of cyclobenzaprine may be considered.
• Sympathomimetic agents: Cyclobenzaprine may potentiate the cardiovascular effects of epinephrine, norepinephrine, and other sympathomimetic amines, increasing the risk of hypertension and cardiac arrhythmias.
• QT‑prolonging drugs: Co‑administration with other drugs known to prolong the QT interval (e.g., certain antiarrhythmics, fluoroquinolone antibiotics, antipsychotics) may increase the risk of cardiac arrhythmias. Avoid when possible.

Practical Advice

• Administration: Take Cyclobenzaprine HCl once daily at approximately the same time each day. Swallow the extended‑release capsule whole with a glass of water, or open it and sprinkle the contents onto a tablespoon of applesauce, which should be consumed immediately without chewing. Rinse your mouth afterward to ensure all medication is swallowed. Taking the medication with food may reduce stomach upset.
• Monitoring: No routine laboratory monitoring is required for short‑term use. For patients with pre‑existing cardiac risk factors, an electrocardiogram (ECG) should be considered before and periodically during treatment. Monitor for signs of excessive sedation, anticholinergic effects (severe dry mouth, difficulty urinating), and serotonin syndrome (agitation, confusion, rapid heart rate, fever, muscle rigidity).
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep out of the reach and sight of children. An overdose of cyclobenzaprine can be fatal, especially in children; store the medication securely.
• Lifestyle: Cyclobenzaprine is most effective when combined with rest and physical therapy as directed by your doctor. Apply ice or heat to the affected area as recommended. Rise slowly from a sitting or lying position to reduce the risk of dizziness or fainting. To relieve dry mouth, sip water frequently, suck on sugarless hard candy, or chew sugarless gum. Avoid alcohol and other CNS depressants. Do not drive or operate machinery until you have determined how the medication affects your alertness.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is close to the time of your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to make up for a missed one.
• When to seek medical review: Contact your doctor immediately if you experience a rapid or irregular heartbeat, severe drowsiness, confusion, difficulty urinating, or signs of serotonin syndrome (agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, or twitching). An overdose is a life‑threatening emergency; call 911 or your local emergency number immediately if an overdose is suspected.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Tizanidine (Zanaflex®): A centrally acting alpha‑2 adrenergic agonist that is the strongest evidence‑based alternative to cyclobenzaprine for acute musculoskeletal pain. It is effective for muscle spasm and neck pain but can cause significant sedation, hypotension, and dry mouth. Unlike cyclobenzaprine, tizanidine requires gradual tapering after long‑term use to prevent rebound hypertension and tachycardia.
• Methocarbamol (Robaxin®): A carbamate derivative that acts centrally to relieve muscle spasm. It is available over‑the‑counter in Canada as Robaxacet® (with acetaminophen) and Robax Platinum® (with ibuprofen), and by prescription at higher doses. It is generally less sedating than cyclobenzaprine but has limited evidence for acute low back pain.
• Baclofen (Lioresal®): A centrally acting muscle relaxant primarily indicated for spasticity associated with spinal cord injury, multiple sclerosis, and other CNS disorders. It is not a first‑line agent for acute mechanical musculoskeletal pain but is sometimes used off‑label for chronic muscle tightness.
• Orphenadrine (Norflex®): An anticholinergic muscle relaxant available by prescription in Canada for acute muscle spasm. It also has analgesic properties but a higher burden of anticholinergic side effects and should be used with caution in the elderly.
• Non‑pharmacological alternatives: Rest, physical therapy, heat/ice application, gentle stretching, and massage are effective first‑line treatments for acute muscle spasm. For fibromyalgia, cognitive‑behavioural therapy (CBT), graded exercise, and sleep hygiene are important non‑drug management strategies.
• Analgesics: Acetaminophen (Tylenol) and non‑steroidal anti‑inflammatory drugs (NSAIDs) such as ibuprofen (Advil/Motrin) and naproxen (Aleve) are first‑line oral agents for acute musculoskeletal pain and may be used as alternatives or adjuncts to muscle relaxants.

Clinical Efficacy

Cyclobenzaprine is one of the most extensively studied skeletal muscle relaxants for the management of acute musculoskeletal conditions. In a systematic review and meta‑analysis of randomized controlled trials, cyclobenzaprine was found to be more effective than placebo in the management of back pain, with a modest but statistically significant effect size. The clinical benefit is greatest in the first few days of treatment, with improvements in muscle spasm, pain, and tenderness typically beginning within 24 to 48 hours. A 2022 pooled analysis confirmed that patients receiving cyclobenzaprine were three times as likely to report overall improvement compared with placebo. For fibromyalgia, a meta‑analysis found that cyclobenzaprine‑treated patients were significantly more likely to report overall improvement and moderate reductions in individual symptoms, particularly sleep disturbance, with a number needed to treat (NNT) of approximately 4 to 5. However, the benefit is offset by a high rate of adverse effects, primarily drowsiness, dry mouth, and dizziness, with a number needed to harm (NNH) of approximately 4. The American College of Physicians and other expert bodies recommend that skeletal muscle relaxants may be considered for acute low back pain when NSAIDs are insufficient, but they emphasize that these agents are associated with a high incidence of CNS adverse effects. Cyclobenzaprine remains the most commonly prescribed muscle relaxant in Canada, valued for its established efficacy and predictable side‑effect profile, though its use should be limited to short‑term courses of 2 to 3 weeks.

Important:

Cyclobenzaprine HCl is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It is intended for short‑term use (2–3 weeks) as an adjunct to rest and physical therapy, not as a long‑term solution for chronic pain. This medication can cause significant drowsiness and dizziness; do not drive, operate heavy machinery, or engage in hazardous activities until you know how it affects you. Alcohol must be strictly avoided during treatment, as the combination can cause severe central nervous system depression. Cyclobenzaprine is contraindicated in patients who have recently had a heart attack, those with heart rhythm problems, heart failure, or an overactive thyroid, and in those taking monoamine oxidase inhibitors (MAOIs). Serotonin syndrome, a potentially life‑threatening condition, can occur if cyclobenzaprine is combined with other serotonergic drugs. Seek immediate medical attention if you experience agitation, confusion, rapid or irregular heartbeat, high fever, muscle rigidity, or seizures. An overdose of cyclobenzaprine can be fatal; store the medication securely out of the reach of children. If you become pregnant, inform your doctor immediately. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Cyclobenzaprine Hcl - Shipping across Canada